Skip to content

Efficacy & safety of Ivabradine versus Beta blocker in Inappropriate Sinus Tachycardia

Effectiveness & safety profile of Ivabradine versus Beta blockers in Inappropriate Sinus Tachycardia Prospective Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/054179
Enrollment
60
Registered
2023-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R000- Tachycardia, unspecified

Interventions

None listed

Sponsors

Kasturba Medical College, Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with IST (resting daytime sinus rate of more than 100 beats per minute and/or average 24-h Holter ECG HR of more than 90 beats per minute) by the treating physician and started on ivabradine or beta blockers during the study period

Exclusion criteria

Exclusion criteria: Secondary causes of sinus tachycardia (including anaemia, hyperthyroidism, infections, hypovolemia, or drugs), previous atrial or ventricular arrhythmias (i.e. atrial fibrillation/flutter, supraventricular arrhythmias, nonsustained or sustained ventricular arrhythmias), structural heart diseases, postural orthostatic tachycardia syndrome, sinus nodal re-entrant tachycardia

Design outcomes

Primary

MeasureTime frame
To Determine & Compare the reduction in resting HR & peak HR of Inappropriate Sinus TachycardiaTimepoint: At follow up after one month

Secondary

MeasureTime frame
1) To study demographic profile of IST patients 2) Collection of Adverse Drug Reactions (ADRs reported) 3) Pharmacoeconomic evaluation of the treatments using a suitable model 4) To assess the quality of life using European Heart Association EHRA score & SF-36 questionnaire Timepoint: At end of study

Countries

India

Contacts

Public ContactDr Harshini H

Kasturba Medical College,Manipal Academy of Higher Education

shalini.adiga@manipal.edu

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026